Beginning a multi-year investment in research funding, which has since yielded the identification of immunotherapeutic targets and led to a clinical trial testing an existing immunotherapy against esophageal cancer at Dana-Farber Cancer Institute.
Beginning a multi-year investment in research funding, which has since yielded the identification of immunotherapeutic targets and led to a clinical trial testing an existing immunotherapy against esophageal cancer at Dana-Farber Cancer Institute.